Effect of methamphetamine in the test of social interaction in adult male rats;Vliv metamfetaminu na test sociálních interakcí u samců laboratorního potkana

Psychiatrie

Volumn 11, Issue SUPPL. 3, 2007, Pages 94-98

  Pometlová, Marie ^a   Mikulecká, Anna ^a   Schutová, Barbora ^a   Hrubá, Lenka ^a   Deykun, Kateryna ^a   Šlamberová, Romana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anxiety; Methamphetamine; Social interaction test

Indexed keywords

METHAMPHETAMINE;

ANXIETY; CONFERENCE PAPER; DRUG EFFECT; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; REARING; SOCIAL INTERACTION; STRESS;

EID: 35148897790     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Arakawa O. Effects of methamphetamine and methylphenidate on single and paired rat open-field behaviors. Physiol Behav 1994;55:441-446.
2. Cadogan AK, Kendall DA, Fink H, Marsden CA. Social interaction increases 5-HT release and cAMP efflux in the rat ventral hippocampus in vivo. Behav Pharmacol 1994;5:299-305.
3. Chaki S, Kawashima N, Suzuki Y, Shimazaki T, Okuyama S. Cocaine- and amphetamine-regulated transcript peptide produces anxiety-like behavior in rodents. Eur J Pharmacol 2003;464:49-54.
4. Clemens KJ, Van Nieuwenhuyzen PS, Li KM, Cornish JL, Hunt GE, McGregor IS. MDMA ("ecstasy"), methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology (Berl) 2004;173:318-325.
5. Couceyro PR, Koylu EO, Kuhar MJ. Further studies on the anatomical distribution of CART by in situ hybridization. J Chem Neuroanat 1997;12:229-241.
6. D'Mello GD, Steckler T. Animal models in cognitive behavioural pharmacology: an overview. Brain Res Cogn Brain Res 1996;3:345-352.
7. Davis M, Whalen PJ. The amygdala: vigilance and emotion. Mol Psychiatry 2001;6:13-34.
8. de Bruin JP, van Oyen HG, Van de Poll N. Behavioural changes following lesions of the orbital prefrontal cortex in male rats. Behav Brain Res 1983;10:209-232.
9. De Vito MJ, Wagner GC. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 1989;28:1145-1150.
10. Duxon MS, Kennett GA, Lightowler S, Blackburn TP, Fone KC. Activation of 5-HT2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology 1997;36:601-608.
11. File SE, Baldwin HA, Johnston AL, Wilks LJ. Behavioral effects of acute and chronic administration of caffeine in the rat. Pharmacol Biochem Behav 1988;30:809-815.
12. File SE, Gonzalez LE, Andrews N. Endogenous acetylcholine in the dorsal hippocampus reduces anxiety through actions on nicotinic and muscatinic1 receptors. Behav Neurosci 1998;112:352-359.
13. File SE, James TA, MacLeod NK. Depletion in amygdaloid 5-hydroxytryptamine concentration and changes in social and aggressive behaviour. J Neural Transm 1981;50:1-12.
14. File SE, Kenny PJ, Cheeta S. The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 2000;66:65-72.
15. File SE, Peet LA. The sensitivity of the rat corticosterone response to environmental manipulations and to chronic chlordiazepoxide treatment. Physiol Behav 1980;25:753-758.
16. File SE, Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 2003;463:35-53.
17. File SE, Vellucci SV, Wendlandt S. Corticosterone - an anxiogenic or an anxiolytic agent? J Pharm Pharmacol 1979;31:300-305.
18. Ge J, Barnes NM, Costall B, Naylor RJ. Effect of aversive stimulation on 5-hydroxytryptamine and dopamine metabolism in the rat brain. Pharmacol Biochem Behav 1997;58:775-783.
19. Gonzalez LE, Andrews N, File SE. 5-HT1A and benzodiazepine receptors in the basolateral amygdala modulate anxiety in the social interaction test, but not in the elevated plus-maze. Brain Res 1996;732:145-153.
20. Gonzalez LE, Rujano M, Tucci S, Paredes D, Silva E, Alba G, Hernandez L. Medial prefrontal transection enhances social interaction. I: behavioral studies. Brain Res 2000;887:7-15.
21. Grace AA. Dopamine. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology. Philadelphia: Lippincott Williams &Wilkins; 2002. p 120-132.
22. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006;6:6.
23. Haughey HM, Brown JM, Wilkins DG, Hanson GR, Fleckenstein AE. Differential effects of methamphetamine on Na(+)/Cl(-)-dependent transporters. Brain Res 2000;863:59-65.
24. Hayase T, Yamamoto Y, Yamamoto K. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. Behav Pharmacol 2005;16:395-404.
25. Higgins GA, Jones BJ, Oakley NR, Tyers MB. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT3 receptor antagonists. Psychopharmacology (Berl) 1991;104:545-551.
26. Hogg S, Andrews N, File SE. Contrasting behavioural effects of 8-OH DPAT in the dorsal raphe nucleus and ventral hippocampus. Neuropharmacology 1994;33:343-348.
27. Holson RR, Walker C. Mesial prefrontal cortical lesions and timidity in rats. II. Reactivity to novel stimuli. Physiol Behav 1986;37:231-238.
28. Iwazaki T, McGregor IS, Matsumoto I. Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res 2006;1097:19-25.
29. Koylu EO, Couceyro PR, Lambert PD, Kuhar MJ. Cocaine- and amphetamine-regulated transcript peptide immunohistochemical localization in the rat brain. J Comp Neurol 1998;391:115-132.
30. Koylu EO, Couceyro PR, Lambert PD, Ling NC, DeSouza EB, Kuhar MJ. Immunohistochemical localization of novel CART peptides in rat hypothalamus, pituitary and adrenal gland. J Neuroendocrinol 1997;9:823-833.
31. Lucot JB, Wagner GC, Schuster CR, Seiden LS. The effects of dopaminergic agents on the locomotor activity of rats after high doses of methylamphetamine. Pharmacol Biochem Behav 1980;13:409-413.
32. Martin P. Animal models sensitive to anti-anxiety agents. Acta Psychiatr Scand Suppl 1998;393:74-80.
33. McDonald RJ, Jones J, Richards B, Hong NS. A double dissociation of dorsal and ventral hippocampal function on a learning and memory task mediated by the dorso-lateral striatum. Eut J Neurosci 2006;24:1789-1801.
34. McHugh SB, Deacon RM, Rawlins JN, Bannerman DM. Amygdala and ventral hippocampus contribute differentially to mechanisms of fear and anxiety. Behav Neurosci 2004;118:63-78.
35. Primus RJ, Kellogg CK. Gonadal hormones during puberty organize environment-related social interaction in the male rat. Horm Behav 1990;24:311-323.
36. Rudnick G, Clark J. From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1993;1144:249-263.
37. Sanders SK, Shekhar A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 1995;52:701-706.
38. Shoblock JR, Maisonneuve IM, Glick SD. Differences between d-methamphetamine and d-amphetamine in rats: working memory, tolerance, and extinction. Psychopharmacology (Berl) 2003;170:150-156.
39. Šlais K, Landa L, Šulcová A. Animální modely úzkostných poruch (Animal models of anxiety disorders). Psychiatrie 2007;11:86-87.
40. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-154.
41. Trivedi MA, Coover GD. Lesions of the ventral hippocampus, but not the dorsal hippocampus, impair conditioned fear expression and inhibitory avoidance on the elevated T-maze. Neurobiol Learn Mem 2004;81:172-184.
42. Tucci S, Contreras Q, Paez X, Gonzalez L, Rada P, Hernandez L. Medial prefrontal transection enhances social interaction. II: neurochemical studies. Brain Res 2000;887:259-265.
43. Votava M, Uhlířová L. Behaviorální preklinické modely úzkosti (Behavioral preclinical models of anxiety) Psychiatrie 2004;8:31-35.
44. Wagner GC, Carelli RM, Jarvis MF. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Pathol Pharmacol 1985;47:221-228.